Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations

Diagnostic Microbiology and Infectious Disease

Volumn 64, Issue 2, 2009, Pages 202-212

  Biedenbach, Douglas J ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Cefditoren; Respiratory tract pathogens; Skin and skin structure infections; Surveillance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAMASE; CEFDINIR; CEFDITOREN; CEFPODOXIME; CEFPROZIL; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; OXACILLIN; PENICILLIN G; PSEUDOMONIC ACID; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EUROPE; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SOUTH AND CENTRAL AMERICA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIA; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; EUROPE; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; RESPIRATORY TRACT INFECTIONS; SKIN DISEASES, BACTERIAL;

EID: 67349266302     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.01.017     Document Type: Article

References (42)

1. Alou L., Gimenez M.J., Sevillano D., Aguilar L., Gonzalez N., Echeverria O., Torrico M., Coronel P., and Prieto J. Are β-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?. J. Antimicrob. Chemother. 59 (2007) 652-657
2. Alvarez-Sala J.L., Kardos P., Martinez-Beltran J., Coronel P., and Aguilar L. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob. Agents Chemother. 50 (2006) 1762-1767
3. Anzueto A., Bishai W.R., and Pottumarthy S. Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis. Diagn. Microbiol. Infect. Dis. 57 (2007) S31-S38
4. Biedenbach D.J., Jones R.N., and Fritsche T.R. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States. Diagn. Microbiol. Infect. Dis. 61 (2008) 240-244
5. Bucko A.D., Hunt B.J., Kidd S.L., and Hom R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin. Ther. 24 (2002) 1134-1147
6. Canut A., Martin-Herrero J., Labora A., and Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J. Antimicrob. Chemother. 60 (2007) 605-612
7. Cao L.D., Naruhiko I., Nobue T., and Yoichi K. Antimicrobial susceptibility of respiratory Haemophilus influenzae strains isolated from pediatric respiratory tract infections. Pediatr. Int. 46 (2004) 419-424
8. Clark C.L., Nagai K., Dewasse B.E., Pankuch G.A., Ednie L.M., Jacobs M.R., and Appelbaum P.C. Activity of cefditoren against respiratory pathogens. J. Antimicrob. Chemother. 50 (2002) 33-41
9. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition, M7-A7 (2006), CLSI, Wayne, PA
10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 18th informational supplement, M100-S18 (2008), CLSI, Wayne, PA
11. Echeverria O., Alou L., Sevillano D., Gonzalez N., Gomez-Lus M.L., Aguilar L., and Prieto J. Pharmacodynamics of simulated total versus free-drug serum concentrations of a low versus a high protein bound third-generation oral cephalosporin (cefpodoxime versus cefditoren) against Streptococcus pneumoniae. J. Chemother. 19 (2007) 288-294
12. Fenoll A., Aguilar L., Robledo O., Gimenez M.J., Tarrago D., Granizo J.J., Gimeno M., and Coronel P. Influence of the β-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media. J. Antimicrob. Chemother. 60 (2007) 323-327
13. Fenoll A., Gimenez M.J., Robledo O., Coronel P., Gimeno M., Casal J., and Aguilar L. Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones. Int. J. Antimicrob. Agents 29 (2007) 224-226
14. Finlay J.E., Miller L.A., and Poupard J.A. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob. Agents Chemother. 41 (1997) 1137-1139
15. Fogarty C.M., Cyganowski M., Palo W.A., Hom R.C., and Craig W.A. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin. Ther. 24 (2002) 1854-1870
16. Fritsche T.R., Biedenbach D.J., and Jones R.N. Update of the activity of cefditoren and comparator oral β-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006). J. Chemother. 20 (2008) 170-174
17. Gracia M., Diaz C., Coronel P., Gimeno M., Garcia-Rodas R., del Prado G., Huelves L., Ruiz V., Naves P.L., Ponte M.C., Granizo J.J., and Soriano F. Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005-06: results of the Cefditoren Surveillance Study. J. Antimicrob. Chemother. 61 (2008) 1180-1181
18. Granizo J.J., Sadaba B., Honorato J., Gimenez M.J., Sevillano D., Aguilar L., and Coronel P. Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers. Int. J. Antimicrob. Agents 31 (2008) 396-398
19. Hasegawa K., Yamamoto K., Chiba N., Kobayashi R., Nagai K., Jacobs M.R., Appelbaum P.C., Sunakawa K., and Ubukata K. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb. Drug Resist. 9 (2003) 39-46
20. Jones R.N., Pfaller M.A., Jacobs M.R., Appelbaum P.C., and Fuchs P.C. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn. Microbiol. Infect. Dis. 41 (2001) 1-14
21. Jose Granizo J., Gimenez M.J., Barberdn J., Coronel P., Gimeno M., and Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin. Ther. 28 (2006) 2061-2069
22. Karlowsky J.A., Critchley I.A., Draghi D.C., Jones M.E., Thornsberry C., and Sahm D.F. Activity of cefditoren against β-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis. Diagn. Microbiol. Infect. Dis. 42 (2002) 53-58
23. Karlowsky J.A., Jones M.E., Draghi D.C., Critchley I.A., Thornsberry C., and Sahm D.F. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn. Microbiol. Infect. Dis. 42 (2002) 59-64
24. Kim I.S., Ki C.S., Kim S., Oh W.S., Peck K.R., Song J.H., Lee K., and Lee N.Y. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. Antimicrob. Agents Chemother. 51 (2007) 453-460
25. Ko K.S., Suh J.Y., Lee M.Y., Lee N.Y., Peck K.R., Kwon K.T., Jung D.S., and Song J.H. In vitro activity of cefditoren against clinical isolates of Escherichia coli from a Korean hospital. Int. J. Antimicrob. Agents 30 (2007) 283-285
26. Lee M.Y., Ko K.S., Oh W.S., Park S., Lee J.Y., Baek J.Y., Suh J.Y., Peck K.R., Lee N.Y., and Song J.H. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Int. J. Antimicrob. Agents 28 (2006) 14-18
27. Lodise T., Kinzig-Schippers M., Drusano G., Loos U., Vogel F., Bulitta J., Hinder M., and Sörgel F. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrob. Agents Chemother. 52 (2008) 1945-1951
28. Nagai K., Davies T.A., Jacobs M.R., and Appelbaum P.C. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2× on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob. Agents Chemother. 46 (2002) 1273-1280
29. Nishi J., Yoshinaga M., Tokuda K., Masuda K., Masuda R., Kamenosono A., Manago K., and Miyata K. Oral antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates from Japanese children. Int. J. Antimicrob. Agents 20 (2002) 130-135
30. Ozaki T., Nishimura N., Suzuki M., Narita A., Watanabe N., Ahn J., Koyama N., Ushida H., Nakane K., Yasuda N., and Funahashi K. Five-day oral cefditoren pivoxil versus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitis. J. Infect. Chemother. 14 (2008) 213-218
31. Poachanukoon O., and Kitcharoensakkul M. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial. Clin. Ther. 30 (2008) 1870-1879
32. Seral C., Suarez L., Rubio-Calvo C., Gomez-Lus R., Gimeno M., Coronel P., Duran E., Becerril R., Oca M., and Castillo F.J. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain. Diagn. Microbiol. Infect. Dis. 62 (2008) 210-215
33. Sevillano D., Gimenez M.J., Alou L., Aguilar L., Cafini F., Torrico M., Gonzalez N., Echeverria O., Coronel P., and Prieto J. Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 60 (2007) 156-158
34. Soriano F., Granizo J.J., Coronel P., Gimeno M., Rodenas E., Gracia M., Garcia C., Fernandez-Roblas R., Esteban J., and Gadea I. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int. J. Antimicrob. Agents 23 (2004) 296-299
35. Soriano F., Granizo J.J., Fenoll A., Gracia M., Fernandez-Roblas R., Esteban J., Gadea I., Coronel P., Gimeno M., Rodenas E., and Santos F. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the Cefditoren Surveillance Program. J. Chemother. 15 (2003) 107-112
36. Stefani S., Mezzatesta M., Fadda G., Mattina R., Palù G., Rossano F., Tufano M., Schito G., and Nicoletti G. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. J. Chemother. (Florence, Italy) 20 (2008) 561
37. Tamura A., Okamoto R., Yoshida T., Yamamoto H., Kondo S., Inoue M., and Mitsuhashi S. In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin. Antimicrob. Agents Chemother. 32 (1988) 1421-1426
38. Torrico M., Aguilar L., Gonzalez N., Gimenez M.J., Echeverria O., Cafini F., Sevillano D., Alou L., Coronel P., and Prieto J. Influence of TEM-1 β-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene. Antimicrob. Agents Chemother. 51 (2007) 3699-3706
39. van Zyl L., le Roux J.G., LaFata J.A., Volk R.S., Palo W.A., Flamm R., and Hom R.C. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. Clin. Ther. 24 (2002) 1840-1853
40. Vazquez J.A., Martin E., Galarza P., Gimenez M.J., Aguilar L., and Coronel P. In vitro susceptibility of Spanish isolates of Neisseria gonorrhoeae to cefditoren and five other antimicrobial agents. Int. J. Antimicrob. Agents 29 (2007) 473-474
41. Wellington K., and Curran M.P. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs 64 (2004) 2597-2618
42. Yamada M., Watanabe T., Miyara T., Baba N., Saito J., Takeuchi Y., and Ohsawa F. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2×: structural basis for its high antimicrobial activity. Antimicrob. Agents Chemother. 51 (2007) 3902-3907